Literature DB >> 33726687

A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.

Jian Xiao1, Wenyun Li2, Yan Huang3, Mengli Huang4, Shanshan Li1, Xiaohui Zhai1, Jing Zhao4, Chan Gao4, Wenzhuan Xie4, Hao Qin5, Shangli Cai4, Yuezong Bai4, Ping Lan6, Yifeng Zou7.   

Abstract

BACKGROUND: Mismatch repair (MMR)/microsatellite instability (MSI) and tumor mutational burden (TMB) are independent biomarkers that complement each other for predicting immune checkpoint inhibitors (ICIs) efficacy. Here we aim to establish a strategy that integrates MSI and TMB determination for colorectal cancer (CRC) in one single assay.
METHODS: Surgical or biopsy specimens retrospectively collected from CRC patients were subjected to NGS analysis. Immunohistochemistry (IHC) and polymerase chain reaction (PCR) were also used to determine MMR/MSI for those having enough tissues. The NGS-MSI method was validated against IHC and PCR. The MSI-high (MSI-H) or microsatellite stable (MSS) groups were further stratified based on tumor mutational burden, followed by validation using the The Cancer Genome Atlas (TCGA) CRC dataset. Immune microenvironment was evaluated for each subgroup be profiling the expression of immune signatures.
RESULTS: Tissues from 430 CRC patients were analyzed using a 381-gene NGS panel. Alterations in KRAS, NRAS, BRAF, and HER2 occurred at a significantly higher incidence among MSI-H tumors than in MSS patients (83.6% vs. 58.4%, p = 0.0003). A subset comprising 98 tumors were tested for MSI/MMR using all three techniques, where NGS proved to be 99.0 and 93.9% concordant with PCR and IHC, respectively. Four of the 7 IHC-PCR discordant cases had low TMB (1.1-8.1 muts/Mb) and were confirmed to have been misdiagnosed by IHC. Intriguingly, 4 of the 66 MSS tumors (as determined by NGS) were defined as TMB-high (TMB-H) using a cut-off of 29 mut/Mb. Likewise, 15 of the 456 MSS tumors in the TCGA CRC cohort were also TMB-H with a cut-off of 9 muts/Mb. Expression of immune signatures across subgroups (MSS-TMB-H, MSI-H-TMB-H, and MSS-TMB-L) confirmed that the microenvironment of the MSS-TMB-H tumors was similar to that of the MSI-H-TMB-H tumors, but significantly more immune-responsive than that of the MSS-TMB-L tumors, indicating that MSI combined with TMB may be more precise than MSI alone for immune microenvironment prediction.
CONCLUSION: This study demonstrated that NGS panel-based method is both robust and tissue-efficient for comprehensive molecular diagnosis of CRC. It also underscores the importance of combining MSI and TMB information for discerning patients with different microenvironment.

Entities:  

Keywords:  Colorectal cancer; Immune checkpoint inhibitor; Microsatellite instability; Next generation sequencing; Tumor mutation burden

Mesh:

Substances:

Year:  2021        PMID: 33726687      PMCID: PMC7962287          DOI: 10.1186/s12885-021-07942-1

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  35 in total

1.  Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function.

Authors:  Louise Klarskov; Susanne Holck; Inge Bernstein; Henrik Okkels; Eva Rambech; Bo Baldetorp; Mef Nilbert
Journal:  Am J Surg Pathol       Date:  2011-09       Impact factor: 6.394

2.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

3.  Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.

Authors:  Jun Gong; Chongkai Wang; Peter P Lee; Peiguo Chu; Marwan Fakih
Journal:  J Natl Compr Canc Netw       Date:  2017-02       Impact factor: 11.908

4.  A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing.

Authors:  Lizhen Zhu; Yanqin Huang; Xuefeng Fang; Chenglin Liu; Wanglong Deng; Chenhan Zhong; Jinghong Xu; Dong Xu; Ying Yuan
Journal:  J Mol Diagn       Date:  2017-12-19       Impact factor: 5.568

5.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Authors:  Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André
Journal:  J Clin Oncol       Date:  2018-01-20       Impact factor: 44.544

Review 6.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

Review 7.  Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.

Authors:  Tristan Snowsill; Helen Coelho; Nicola Huxley; Tracey Jones-Hughes; Simon Briscoe; Ian M Frayling; Chris Hyde
Journal:  Health Technol Assess       Date:  2017-09       Impact factor: 4.014

8.  Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer.

Authors:  Ji-Hyun Lee; Deborah Cragun; Zachary Thompson; Domenico Coppola; Santo V Nicosia; Mohammad Akbari; Shiyu Zhang; John McLaughlin; Steven Narod; Joellen Schildkraut; Thomas A Sellers; Tuya Pal
Journal:  Genet Test Mol Biomarkers       Date:  2014-03-04

9.  Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases.

Authors:  Gulden Diniz; Safiye Aktas; Cankut Cubuk; Ragip Ortac; Canan Vergin; Nur Olgun
Journal:  Pediatr Hematol Oncol       Date:  2013-05       Impact factor: 1.969

10.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.

Authors:  Peng Jiang; Shengqing Gu; Deng Pan; Jingxin Fu; Avinash Sahu; Xihao Hu; Ziyi Li; Nicole Traugh; Xia Bu; Bo Li; Jun Liu; Gordon J Freeman; Myles A Brown; Kai W Wucherpfennig; X Shirley Liu
Journal:  Nat Med       Date:  2018-08-20       Impact factor: 53.440

View more
  13 in total

1.  Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer.

Authors:  Zhaofei Zhou; Kang Li; Qiang Wei; Lingxiang Chen; You Shuai; Yajing Wang; Kang He; Lixiang Si; Yuejiao Zhong; Jianwei Lu
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  Importance of Early Next-Generation Sequencing in Microsatellite Unstable Colon Cancer With a High Tumor Mutation Burden.

Authors:  Sethi Ashish; Moses Raj
Journal:  Cureus       Date:  2022-03-06

3.  TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer.

Authors:  Junjie Chen; Anwaier Apizi; Lin Wang; Guanting Wu; Zheng Zhu; Huihui Yao; Guoliang Chen; Xinyu Shi; Bo Shi; Qingliang Tai; Chenglong Shen; Guoqiang Zhou; Lingzhi Wu; Songbing He
Journal:  J Gastrointest Oncol       Date:  2021-10

4.  Characterizing HDAC Pathway Copy Number Variation in Pan-Cancer.

Authors:  Shuming Yang; Shengzhi Xie; Xinying Shi; Dan Su; Bo He; Yang Xu; Zhefeng Liu
Journal:  Pathol Oncol Res       Date:  2022-06-13       Impact factor: 2.874

Review 5.  Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Yavar Shiravand; Faezeh Khodadadi; Seyyed Mohammad Amin Kashani; Seyed Reza Hosseini-Fard; Shadi Hosseini; Habib Sadeghirad; Rahul Ladwa; Ken O'Byrne; Arutha Kulasinghe
Journal:  Curr Oncol       Date:  2022-04-24       Impact factor: 3.109

6.  OncoPan®: An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma.

Authors:  Maria Grazia Tibiletti; Ileana Carnevali; Valeria Pensotti; Anna Maria Chiaravalli; Sofia Facchi; Sara Volorio; Frederique Mariette; Paolo Mariani; Stefano Fortuzzi; Marco Alessandro Pierotti; Fausto Sessa
Journal:  Biomedicines       Date:  2022-05-23

7.  Cancer Comprehensive Analysis in Gastric Carcinoma: Benefits and New Perspectives.

Authors:  Vasiliki Pisanidou; Panagiotis Apostolou; Georgios Beis; Eleana Hatzidaki; Ioannis Papasotiriou
Journal:  Case Rep Oncol       Date:  2021-11-25

8.  ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma via Pan-Carcinoma Synthesis.

Authors:  Yanna Zhang; Ting Du; Xiancheng Chen
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

9.  Analysis of transcript-wide profile regulated by microsatellite instability of colorectal cancer.

Authors:  Ying Xu; Xiaofeng Wang; Yimin Chu; Ji Li; Weiyi Wang; Xiangyu Hu; Fengli Zhou; Haiqin Zhang; Lu Zhou; Rong Kuai; Yunfei Jin; Daming Yang; Haixia Peng
Journal:  Ann Transl Med       Date:  2022-02

Review 10.  Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.

Authors:  Martina Amato; Renato Franco; Gaetano Facchini; Raffaele Addeo; Fortunato Ciardiello; Massimiliano Berretta; Giulia Vita; Alessandro Sgambato; Sandro Pignata; Michele Caraglia; Marina Accardo; Federica Zito Marino
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.